OMGA - Omega Therapeutics, Inc.
IEX Last Trade
0.8462
-0.624 -73.718%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:22:04 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$1.47
-0.62
-42.44%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.56%
1 Month
-3.01%
3 Months
-33.95%
6 Months
-65.33%
1 Year
-66.31%
2 Year
-83.84%
Key data
Stock price
$0.85
DAY RANGE
$0.82 - $1.47
52 WEEK RANGE
$0.79 - $6.30
52 WEEK CHANGE
-$74.07
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Mahesh Karande
Region: US
Website: omegatherapeutics.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: omegatherapeutics.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Recent news